Trial Profile
Phase II study of Erlotinib for previously treated advanced or recurrent non-small-cell lung cancer with EGFR wild type and KRAS wild type
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 27 Jul 2015
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 13 Jul 2012 New trial record